Status:

RECRUITING

MDR - PMCF Study for Taperloc Complete Stems

Lead Sponsor:

Zimmer Biomet

Conditions:

Hip Arthritis

Hip Disease

Eligibility:

All Genders

18+ years

Brief Summary

The objective of this consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Taperloc Complete stems when used for primary or revision total hip ...

Detailed Description

The objective of this consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Taperloc Complete stems when used for primary or revision total hip ...

Eligibility Criteria

Inclusion

  • Patient must be 18 years of age or older and skeletally mature
  • Patient must be willing and able to sign IRB approved informed consent
  • Patient must have undergone primary or revision hip arthroplasty with the -Taperloc Complete stem according to a cleared indication, which includes the following:
  • Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
  • Rheumatoid arthritis
  • Correction of functional deformity
  • Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques

Exclusion

  • Off-label use
  • Infection
  • Sepsis
  • Osteomyelitis
  • Uncooperative patient or patient with neurologic disorders who are incapable of following directions
  • Osteoporosis
  • Metabolic disorders which may impair bone formation
  • Osteomalacia
  • Distant foci of infections which may spread to the implant site
  • Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram
  • Vascular insufficiency, muscular atrophy, or neuromuscular disease
  • Patient is known to be pregnant or nursing
  • Patient is a prisoner
  • Patient is a known alcohol or drug abuser
  • Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent

Key Trial Info

Start Date :

February 13 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

February 12 2032

Estimated Enrollment :

820 Patients enrolled

Trial Details

Trial ID

NCT04028687

Start Date

February 13 2020

End Date

February 12 2032

Last Update

March 11 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Orthopaedic Institute of Henderson

Henderson, Nevada, United States, 89052

2

Texas Health Physicians Group

Plano, Texas, United States, 75243

3

Proliance Orthopaedics and Sports Medicine

Bellevue, Washington, United States, 98004

MDR - PMCF Study for Taperloc Complete Stems | DecenTrialz